Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 915-922

  Iqbal, Javaid ^a   Andrew, Ruth ^a   Cruden, Nicholas L ^a   Kenyon, Christopher J ^a   Hughes, Katherine A ^a   Newby, David E ^a   Hadoke, Patrick W F ^a   Walker, Brian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 [2H] 2 CORTISONE; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 9,11,12,12 [2H] 4 CORTISOL; ALDOSTERONE; CANRENOATE POTASSIUM; CORTISONE; CORTISONE DERIVATIVE; HYDROCORTISONE; HYDROCORTISONE DERIVATIVE; MINERALOCORTICOID ANTAGONIST; TRACER; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY SINUS; CORONARY SINUS BLOOD FLOW; DOPPLER FLOWMETER; ENZYME ACTIVITY; FEMALE; FEMORAL ARTERY; HEART FAILURE; HEART MUSCLE; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; PHLEBOGRAPHY; PRIORITY JOURNAL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; AGED; CANRENOIC ACID; CORTISONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; RECEPTORS, MINERALOCORTICOID;

EID: 84895836233     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2049     Document Type: Article

References (47)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
2. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
4. Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958-1966.
5. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575. (Pubitemid 23208145)
6. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005; 90:5070-5076. (Pubitemid 41262256)
7. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191-202.
8. Pitt B. Plasma aldosterone levels in patients with coronary artery disease without heart failure or myocardial infarction: implications for pathophsiology, prognosis, and therapy. Eur Heart J. 2012;33:162-164.
9. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585. (Pubitemid 18263202)
10. Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
11. Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
12. Slight SH, Ganjam VK, Gómez-Sánchez CE, Zhou MY, Weber KT. High affinity NAD(+)-dependent 11 β-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol. 1996;28:781-787.
13. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab. 2000;85: 2519-2525. (Pubitemid 32269210)
14. Chai W, Hofland J, Jansen PM, et al. Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors? J Hypertens. 2010;28:1044-1053.
15. Hughes KA, Manolopoulos KN, Iqbal J, et al. Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes. 2012;61:1357-1364.
16. Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142:1371-1376. (Pubitemid 32299662)
17. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J Clin Endocrinol Metab. 2002;87:277-285. (Pubitemid 34084702)
18. Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes. 2004;53:2051-2059. (Pubitemid 38970754)
19. Andrew R, Westerbacka J, Wahren J, Yki-Järvinen H, Walker BR. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes. 2005;54:1364-1370. (Pubitemid 40586665)
20. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009;58:46-53.
21. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
22. Mattsson C, Reynolds RM, Simonyte K, Olsson T, Walker BR. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. J Clin Endocrinol Metab. 2009;94: 1347-1352.
23. Al-Dujaili EA, Mullins LJ, Bailey MA, Kenyon CJ. Development of a highly sensitive ELISA for aldosterone in mouse urine: validation in physiological and pathophysiological states of aldosterone excess and depletion. Steroids. 2009;74:456-462.
24. Brown BG, Josephson MA, Petersen RB, et al. Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease. Am J Cardiol. 1981;48:1077-1085. (Pubitemid 12004716)
25. Bagger JP. Coronary sinus blood flow determination by the thermodilution technique: influence of catheter position and respiration. Cardiovasc Res. 1985;19:27-31. (Pubitemid 15198949)
26. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286-290.
27. Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CR. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf). 1989;31:355-361. (Pubitemid 19219243)
28. Hellman L, Nakada F, Zumoff B, Fukushima D, Bradlow HL, Gallagher TF. Renal capture and oxidation of cortisol in man. J Clin Endocrinol Metab. 1971;33:52-62.
29. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR. Mineralocorticoid excess and inhibition of 11 β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf). 1992;37:483-492.
30. Noto G, Pravatá G, Bongiorno MR, Bosco M, Arico M. Topical canrenoic acid. Quantification of the antiandrogenic activity in the hamster flank organ. Int J Dermatol. 1991;30:810-813.
31. Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf). 1985;23:341-347. (Pubitemid 16216752)
32. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975;97:52-58.
33. Caballero R, Moreno I, González T, et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation. 2003;107:889-895. (Pubitemid 36241049)
34. Gómez R, Núñez L, Caballero R, Vaquero M, Tamargo J, Delpon E. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. Br J Pharmacol. 2005; 146:146-161. (Pubitemid 43086104)
35. Finotti P, Palatini P. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. J Pharmacol Exp Ther. 1981;217:784-790. (Pubitemid 11082270)
36. Abshagen U, Spörl S, L'age M. Non-interaction of spironolactone medication and cortisol metabolism in man. Klin Wochenschr. 1978;56:135-138. (Pubitemid 8262680)
37. Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160:642-648.
38. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77. (Pubitemid 32050438)
39. Ruzicka M, Coletta E, White R, Davies R, Haddad H, Leenen FH. Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE". Am J Hypertens. 2010;23:1179-1182.
40. Messaoudi S, Gravez B, Tarjus A, et al. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension. 2013;61:361-367.
41. Hunt SA, Abraham WT, Chin MH, 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
42. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
43. Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009;156:689-712.
44. Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol. 2003;41:2275-2279. (Pubitemid 36724279)
45. Baykan M, Erem C, Gedikli O, et al. Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing's Syndrome. Echocardiography. 2008;25:182-190. (Pubitemid 351198994)
46. Reynolds RM, Labad J, Strachan MW, et al. Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J Clin Endocrinol Metab. 2010;95:1602-1608.
47. Small GR, Hadoke PW, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005;102:12165-12170. (Pubitemid 41291146)